JP2018033353A5 - - Google Patents

Download PDF

Info

Publication number
JP2018033353A5
JP2018033353A5 JP2016168499A JP2016168499A JP2018033353A5 JP 2018033353 A5 JP2018033353 A5 JP 2018033353A5 JP 2016168499 A JP2016168499 A JP 2016168499A JP 2016168499 A JP2016168499 A JP 2016168499A JP 2018033353 A5 JP2018033353 A5 JP 2018033353A5
Authority
JP
Japan
Prior art keywords
gene
expression control
expression
nucleic acid
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016168499A
Other languages
Japanese (ja)
Other versions
JP6934235B2 (en
JP2018033353A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2016168499A priority Critical patent/JP6934235B2/en
Priority claimed from JP2016168499A external-priority patent/JP6934235B2/en
Publication of JP2018033353A publication Critical patent/JP2018033353A/en
Publication of JP2018033353A5 publication Critical patent/JP2018033353A5/ja
Application granted granted Critical
Publication of JP6934235B2 publication Critical patent/JP6934235B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (10)

下記（ａ）〜（ｃ）からなる群から選択された少なくとも一つのポリヌクレオチドからなることを特徴とする癌関連遺伝子の発現を制御する発現制御核酸分子。
（ａ）配列番号１〜６のいずれかの塩基配列からなるポリヌクレオチド
（ｂ）前記（ａ）のいずれかの塩基配列において、１もしくは数個の塩基が欠失、置換、挿入および／または付加された塩基配列からなり、前記癌関連遺伝子の発現を制御するポリヌクレオチド
（ｃ）前記（ａ）のいずれかの塩基配列に対して、８０％以上の同一性を有する塩基配列からなり、前記癌関連遺伝子の発現を制御するポリヌクレオチド An expression control nucleic acid molecule that controls expression of a cancer-related gene, comprising at least one polynucleotide selected from the group consisting of the following (a) to (c):
(A) A polynucleotide comprising any one of the nucleotide sequences of SEQ ID NOS: 1 to 6 (b) In the nucleotide sequence of any one of (a), one or several bases are deleted, substituted, inserted and / or added. A polynucleotide that controls expression of the cancer-related gene (c), a nucleotide sequence having 80% or more identity to any one of the nucleotide sequences of (a), and the cancer Polynucleotides that control the expression of related genes 前記ポリヌクレオチドが、分子内でステムループ構造を形成する、請求項１記載の発現制御核酸分子。 The expression control nucleic acid molecule according to claim 1, wherein the polynucleotide forms a stem-loop structure in the molecule. 前記癌関連遺伝子が、ＭＥＴ遺伝子、ＣＤＫ２ＡＰ１遺伝子、ＳＵＶ３９Ｈ１遺伝子、ＣＣＬ２遺伝子およびＡＢＣＣ６からなる群から選択された少なくとも一つである、請求項１または２記載の発現制御核酸分子。 The expression control nucleic acid molecule according to claim 1 or 2, wherein the cancer-related gene is at least one selected from the group consisting of a MET gene, a CDK2AP1 gene, a SUV39H1 gene, a CCL2 gene, and ABCC6. 前記癌関連遺伝子の発現を抑制する、請求項３記載の発現制御核酸分子。 The expression control nucleic acid molecule according to claim 3, which suppresses expression of the cancer-related gene. 請求項１から４のいずれか一項に記載の発現制御核酸分子を使用することを特徴とする標的遺伝子の発現を制御する発現制御方法。 An expression control method for controlling expression of a target gene, comprising using the expression control nucleic acid molecule according to any one of claims 1 to 4. 前記発現制御核酸分子を、細胞、組織または器官に投与する工程を含む、請求項５記載の発現制御方法。 The expression control method according to claim 5, comprising a step of administering the expression control nucleic acid molecule to a cell, tissue or organ. 前記発現制御核酸分子を、ｉｎ ｖｉｖｏまたはｉｎ ｖｉｔｒｏで投与する、請求項５または６記載の発現制御方法。 The expression control method according to claim 5 or 6, wherein the expression control nucleic acid molecule is administered in vivo or in vitro . 前記発現制御核酸分子を、非ヒト動物に投与する、請求項５または６記載の発現制御方法。 The expression control method according to claim 5 or 6, wherein the expression control nucleic acid molecule is administered to a non-human animal. 標的遺伝子が、ＭＥＴ遺伝子、ＣＤＫ２ＡＰ１遺伝子、ＳＵＶ３９Ｈ１遺伝子、ＣＣＬ２遺伝子およびＡＢＣＣ６からなる群から選択された少なくとも一つの癌関連遺伝子である、請求項５から８のいずれか一項に記載の発現制御方法。 The expression control method according to any one of claims 5 to 8, wherein the target gene is at least one cancer-related gene selected from the group consisting of a MET gene, a CDK2AP1 gene, a SUV39H1 gene, a CCL2 gene, and ABCC6. 前記標的遺伝子の発現を抑制する、請求項９記載の発現制御方法。
The expression control method according to claim 9, wherein the expression of the target gene is suppressed.
JP2016168499A 2016-08-30 2016-08-30 Expression-controlled nucleic acid molecules for gene expression control and their uses Active JP6934235B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016168499A JP6934235B2 (en) 2016-08-30 2016-08-30 Expression-controlled nucleic acid molecules for gene expression control and their uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016168499A JP6934235B2 (en) 2016-08-30 2016-08-30 Expression-controlled nucleic acid molecules for gene expression control and their uses

Publications (3)

Publication Number Publication Date
JP2018033353A JP2018033353A (en) 2018-03-08
JP2018033353A5 true JP2018033353A5 (en) 2019-09-12
JP6934235B2 JP6934235B2 (en) 2021-09-15

Family

ID=61564621

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016168499A Active JP6934235B2 (en) 2016-08-30 2016-08-30 Expression-controlled nucleic acid molecules for gene expression control and their uses

Country Status (1)

Country Link
JP (1) JP6934235B2 (en)

Similar Documents

Publication Publication Date Title
Beauchemin et al. Dynamic microRNA-101a and Fosab expression controls zebrafish heart regeneration
JP2015142558A5 (en)
JP2017532042A5 (en)
JP2018512041A5 (en)
WO2016094845A3 (en) Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
JP2018512110A5 (en)
JP2014527401A5 (en)
JP2016508715A5 (en)
JP2017523777A5 (en)
EA201791820A1 (en) OLIGONUCLEOTIC THERAPY OF CONGENITAL AMAUROSIS LEBER
MX2021000128A (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues.
JP2016521554A5 (en)
Wells The myth of junk DNA
JP2009219504A5 (en)
JP2015507625A5 (en)
JP2018530530A5 (en)
JP2014514921A5 (en)
WO2012092569A3 (en) Compositions comprising immunostimulatory nucleic acids and related methods
BR112021007403A2 (en) Compositions and methods for transgene delivery
JP2019527563A5 (en)
WO2011142798A3 (en) Methods of preparing targeted aptamer prodrugs
EA201892366A1 (en) ANTISMINAL OLIGOMERS AND METHODS OF THEIR APPLICATION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE GENE OF THE ACID ALPHA-GLUCOSIDASE
Dong et al. Non-coding RNAs: Important participants in cardiac fibrosis
RU2016131028A (en) COMPOSITIONS CONTAINING ASYMMETRIC INTERFERING RNA WHICH ARE K-RAS SILENCED AND WAYS OF APPLICATION
JP2018033353A5 (en)